Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
04/2003
04/30/2003CN1413633A Medicine for treating diabetes
04/30/2003CN1413624A New medicine for treating diabetes
04/30/2003CN1413598A Manufacture technology of nano bee glue
04/30/2003CN1413596A Yoghurt containing ossein protein capsule, chewing tablet and its preparation method
04/30/2003CN1413582A Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
04/30/2003CN1413576A Solid-state liposome containing calcareous and its preparation method
04/30/2003CN1107066C Diaza-spiro [3,5] nonane derivatives
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106851C 三七胶囊 Thirty-seven Capsules
04/30/2003CN1106849C Hypoglycemic capsules
04/30/2003CN1106840C Naringin and naringenin as 3-hydroxyl-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555586 Treating obesity, anxiety disorder, post-traumatic stress disorder, premenstrual syndrome, attention deficit disorder, Tourette syndrome, bulimia nervosa or Shy Drager Syndrome by administering a hydroxycycloalkanephenethyl amine
04/29/2003US6555578 Thyromimetic antiobesity agents
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555570 Growth hormone secretagogous with improved bioavailability
04/29/2003US6555568 3-(4,5,7-trifluorobenzothiazol-2-yl)methyl-indole-N-acetic acid, ethyl ester for example; treating angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
04/29/2003US6555536 Antiproliferative agents; antidiabetic agents
04/29/2003US6555531 Weight promoting composition, method, and product
04/29/2003US6555530 Administering a mixture of selective estrogen receptor modulators (SERMs), or estrogens with delta-gonadien-21-ol-3,20-diones of given formula
04/29/2003US6555519 O-glucosylated benzamide SGLT2 inhibitors and method
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555352 Peptide for use in human therapeutics and diagnostic compositions
04/29/2003US6555135 Comicronized with excipient having no therapeutic activity that is not a surfactant.
04/29/2003US6555134 Synergistic mixtures of garlic and lycopene for preventing LDL oxidation
04/29/2003US6555113 Elevating the ratio of circulating HDL to circulating LDL by administering a peptide conjugate of a helper T cell epitope portion linked to a B cell epitope portion; decrease in development of atherosclerotic lesions
04/29/2003CA2134347C Thiazole or imidazole derivatives as maillard reaction inhibitors
04/25/2003CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
04/24/2003WO2003034275A2 Chimeric glycosylphosphatidylinositol containing peptides
04/24/2003WO2003033808A2 Composition and method for treating diabetes
04/24/2003WO2003033734A2 Diagnostic tests for the diagnosis of copper storage disease
04/24/2003WO2003033697A1 Conversion of liver stem and progenitor cells to pancreatic functional cells
04/24/2003WO2003033685A2 Method of producing human beta cell lines
04/24/2003WO2003033681A2 Composition comprising a lactobacillus pentosus strain and uses thereof
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
04/24/2003WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor
04/24/2003WO2003033632A1 Cholesterol lowering structured lipids with omega 6 pufa
04/24/2003WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
04/24/2003WO2003033534A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033524A2 Peptidyl ketones as inhibitors of dpiv
04/24/2003WO2003033513A1 Differentially expressed genes associated with obesity and type 2 diabetes
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033497A1 Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
04/24/2003WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors
04/24/2003WO2003033493A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033480A1 Lactam derivatives as antagonists for human 11cby receptors
04/24/2003WO2003033476A1 Pyrimidinones as melanin concentrating hormone receptor 1
04/24/2003WO2003033470A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003WO2003033467A1 Nitroso diphenylamine derivatives as nitrogen monoxide generating agents
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033453A1 Dicarboxylic acid derivatives, their preparation and therapeutical use
04/24/2003WO2003033445A1 Stabilized compositions of aqueous reduced coenzyme q solution
04/24/2003WO2003033023A1 Drugs ameliorating hypo-hdl cholesterolemia
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003032993A1 Use of phosphorodiesterase iv inhibitors
04/24/2003WO2003032991A1 N-aroyl piperazine derivatives as orexin receptor antagonists
04/24/2003WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032969A2 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
04/24/2003WO2003032967A1 Method of stabilizing reduced coenzyme q10
04/24/2003WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
04/24/2003WO2003032963A2 Method of reducing type 2 diabetes in high risk patients
04/24/2003WO2003032955A1 Highly compressible ethylcellulose for tableting
04/24/2003WO2003032923A2 Induction of beta cell differentiation in human cells
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032894A2 Method of monitoring neuroprotective treatment
04/24/2003WO2003032810A2 Treatment and diagnosis of insulin resistant states
04/24/2003WO2003032753A1 Use of cystathionine
04/24/2003WO2003011887A3 Antisense modulation of apolipoprotein b expression
04/24/2003WO2002096353A3 Polymer controlled induced viscosity fiber system and uses thereof
04/24/2003WO2002070011A3 Treatment of ppar mediated diseases
04/24/2003WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis
04/24/2003WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
04/24/2003WO2002058690A3 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
04/24/2003WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002046227A3 Glp-1 fusion proteins
04/24/2003WO2002038171A3 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
04/24/2003WO2002031498A3 Protecting therapeutic compositions from host-mediated inactivation
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003WO2002024180A3 Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
04/24/2003WO2002017734A3 Materials and methods for the treatment or prevention of obesity
04/24/2003WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase
04/24/2003US20030078426 Thiazolidine or oxazolidine compounds useful for preventing or therapeutical agents for various diseases such as diabetes and hyperlipemia
1 ... 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 ... 1298